Literature DB >> 16603451

Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles.

Vivek Mishra1, Sunil Mahor, Amit Rawat, Prem N Gupta, Praveen Dubey, Kapil Khatri, Suresh P Vyas.   

Abstract

Hydrophilic drugs/peptides have poor cross Blood-brain permeability. Various drug delivery systems with diverse surfacial characteristics have been reported for effective translocation of drugs across Blood-brain barrier. In present investigation, the potential of engineered albumin nanoparticles was evaluated for brain specific delivery after intravenous administration. Long circulatory PEGylated albumin nanoparticles encapsulating water-soluble antiviral drug azidothymidine (AZT) were prepared by ultra-emulsification method using chemical cross-linking by glutaraldehyde. Surface of the PEGylated nanoparticles was modified by anchoring transferrin as a ligand for brain targeting. Nanoparticles were characterized for their size, polydispersity, surfacial charge, drug loading and in vitro drug release. Fluorescence studies revealed the enhanced uptake of transferrin-anchored nanoparticles in the brain tissues when compared with unmodified nanoparticles. In vivo evaluation was carried out on albino rats to evaluate tissue distribution of engineered nanoparticles after intravenous administration. A significant ((*)P < 0.01) enhancement of brain localization of AZT was observed for transferrin anchored pegylated albumin nanopariticles (Tf-PEG-NPs). Hence, the specific role of transferrin ligand on nanoparticles for brain targeting was confirmed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16603451     DOI: 10.1080/10611860600612953

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  28 in total

Review 1.  In vivo methods to study uptake of nanoparticles into the brain.

Authors:  Inge van Rooy; Serpil Cakir-Tascioglu; Wim E Hennink; Gert Storm; Raymond M Schiffelers; Enrico Mastrobattista
Journal:  Pharm Res       Date:  2010-10-07       Impact factor: 4.200

Review 2.  Endocytic mechanisms for targeted drug delivery.

Authors:  Lisa M Bareford; Peter W Swaan
Journal:  Adv Drug Deliv Rev       Date:  2007-06-28       Impact factor: 15.470

Review 3.  Blood-brain barrier transport of therapeutics via receptor-mediation.

Authors:  Angela R Jones; Eric V Shusta
Journal:  Pharm Res       Date:  2007-07-10       Impact factor: 4.200

Review 4.  Nanoparticulate systems for growth factor delivery.

Authors:  Sufeng Zhang; Hasan Uludağ
Journal:  Pharm Res       Date:  2009-05-05       Impact factor: 4.200

5.  In vitro and initial in vivo evaluation of (68)Ga-labeled transferrin receptor (TfR) binding peptides as potential carriers for enhanced drug transport into TfR expressing cells.

Authors:  Carmen Wängler; Dina Nada; Georg Höfner; Simone Maschauer; Björn Wängler; Stephan Schneider; Esther Schirrmacher; Klaus T Wanner; Ralf Schirrmacher; Olaf Prante
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

Review 6.  Targeting anti-HIV drugs to the CNS.

Authors:  Kavitha S Rao; Anuja Ghorpade; Vinod Labhasetwar
Journal:  Expert Opin Drug Deliv       Date:  2009-08       Impact factor: 6.648

Review 7.  Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art.

Authors:  Luisa Fiandra; Amedeo Capetti; Luca Sorrentino; Fabio Corsi
Journal:  J Neuroimmune Pharmacol       Date:  2016-11-10       Impact factor: 4.147

Review 8.  Developing therapeutic antibodies for neurodegenerative disease.

Authors:  Y Joy Yu; Ryan J Watts
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

Review 9.  Biomaterials for Enhancing CNS Repair.

Authors:  Teck Chuan Lim; Myron Spector
Journal:  Transl Stroke Res       Date:  2016-06-01       Impact factor: 6.829

Review 10.  A translational approach to congenital non-obstructive hydronephrosis.

Authors:  Robyn P Thom; Norman D Rosenblum
Journal:  Pediatr Nephrol       Date:  2012-10-05       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.